- Conditions
- Adult Glioblastoma Multiforme
- Interventions
- olaratumab, ramucirumab
- Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 1,033
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glioblastoma
- Interventions
- bosutinib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Recurrent Glioblastoma
- Interventions
- Nivolumab 240 mg IV, Nivolumab 3 mg/kg, Ipilimumab 1 mg/kg, NovoTTF200A (Optune)
- Drug · Device
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- temozolomide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Brain Cancer
- Interventions
- Vorasidenib, Lomustine
- Drug
- Lead sponsor
- Megan Mantica
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- terameprocol, pharmacological study
- Drug · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- carboplatin
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2000
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Brain Tumor, Glioblastoma, Anaplastic Glioma
- Interventions
- everolimus, sorafenib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Glioblastoma
- Interventions
- Zimberelimab, Domvanalimab, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- San Francisco, California • New Haven, Connecticut • Boston, Massachusetts
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer
- Interventions
- pemetrexed
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2022
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- lonafarnib
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 9
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- temozolomide 60 mg x 21 days, temozolomide 75 mg x 21 days, ABT-888 20 mg x 21 days, ABT-888 40 mg x 21 days, Temozolomide 150 mg x 5 days, ABT-888 40 mg x 5 days
- Drug
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 17
- States / cities
- La Jolla, California • Los Angeles, California • Honolulu, Hawaii + 11 more
- Conditions
- Adult Anaplastic Astrocytoma, Recurrent Grade III Glioma, Recurrent Grade IV Glioma, Adult Anaplastic Oligodendroglioma, Adult Brain Tumor, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Tumor, Adult Anaplastic Oligoastrocytoma, Recurrent High Grade Glioma
- Interventions
- flucytosine, polymerase chain reaction, immunohistochemistry staining method, gene therapy, pharmacological study, 3-Tesla magnetic resonance imaging, laboratory biomarker analysis, therapeutic conventional surgery, E. coli CD-expressing genetically modified neural stem cells
- Drug · Other · Biological + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- aldesleukin, lymphokine-activated killer cells
- Biological
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Staten Island, New York
- Conditions
- Recurrent Glioblastoma, Recurrent Astrocytoma, Recurrent Oligodendroglioma, Recurrent Glioma
- Interventions
- Niraparib
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Recurrent CNS Tumors, Brain Cancer, Gliomas, IDH-wildtype Gliomas, IDH-mutant Gliomas, Rare CNS Tumor
- Interventions
- SmartMatch testing
- Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years to 120 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- talampanel
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Glioblastoma, Recurrent Glioblastoma
- Interventions
- ASP8374, cemiplimab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Cincinnati, Ohio + 1 more
- Conditions
- Glioblastoma
- Interventions
- Tofacitinib 10mg, Temozolomide, Lomustine
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Leukemia, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- psychosocial assessment and care
- Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2005
- U.S. locations
- 26
- States / cities
- Sacramento, California • Gainesville, Florida • Miami, Florida + 23 more
- Conditions
- Anaplastic Astrocytoma, Glioblastoma
- Interventions
- trabedersen, temozolomide, Drug delivery system for administration of AP 12009, Placement of Drug Delivery System, carmustine, lomustine
- Drug · Device · Procedure
- Lead sponsor
- Isarna Therapeutics GmbH
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 3
- States / cities
- Edison, New Jersey • Mineola, New York • Rochester, New York
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm
- Interventions
- Vorinostat, Stereotactic Radiosurgery, Laboratory Biomarker Analysis, Pharmacological Study, Therapeutic Conventional Surgery
- Drug · Radiation · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glioblastoma Multiforme
- Interventions
- Temozolomide, bevacizumab and bortezomib
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Adult Brain Tumor, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Interventions
- conventional surgery, tandutinib, pharmacological study, Tissue samples
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more